HK1204477A1 - Single domain antibodies as inhibitors of pcsk9 pcsk9 - Google Patents

Single domain antibodies as inhibitors of pcsk9 pcsk9

Info

Publication number
HK1204477A1
HK1204477A1 HK15104974.5A HK15104974A HK1204477A1 HK 1204477 A1 HK1204477 A1 HK 1204477A1 HK 15104974 A HK15104974 A HK 15104974A HK 1204477 A1 HK1204477 A1 HK 1204477A1
Authority
HK
Hong Kong
Prior art keywords
pcsk9
inhibitors
single domain
domain antibodies
antibodies
Prior art date
Application number
HK15104974.5A
Other languages
English (en)
Chinese (zh)
Inventor
‧賽義達
‧張
Original Assignee
Adaerata Ltd Partnership
Nat Res Council Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaerata Ltd Partnership, Nat Res Council Canada filed Critical Adaerata Ltd Partnership
Publication of HK1204477A1 publication Critical patent/HK1204477A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G01N33/5735—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes co-enzymes or co-factors, e.g. NAD, ATP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK15104974.5A 2011-12-20 2015-05-26 Single domain antibodies as inhibitors of pcsk9 pcsk9 HK1204477A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161578000P 2011-12-20 2011-12-20
PCT/CA2012/050923 WO2013091103A1 (fr) 2011-12-20 2012-12-20 Anticorps à domaine unique en tant qu'inhibiteurs de pcsk9

Publications (1)

Publication Number Publication Date
HK1204477A1 true HK1204477A1 (en) 2015-11-20

Family

ID=48667583

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104974.5A HK1204477A1 (en) 2011-12-20 2015-05-26 Single domain antibodies as inhibitors of pcsk9 pcsk9

Country Status (7)

Country Link
US (1) US9879093B2 (fr)
EP (1) EP2794661B1 (fr)
JP (1) JP6170940B2 (fr)
CN (1) CN104169304A (fr)
CA (1) CA2859226C (fr)
HK (1) HK1204477A1 (fr)
WO (1) WO2013091103A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
AU2014235430A1 (en) * 2013-03-15 2015-09-24 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 (PCSK9)
WO2015017791A1 (fr) * 2013-08-01 2015-02-05 Atherotech, Inc. Analyse de la fonction de pcsk9
GB2521356B (en) * 2013-12-17 2018-10-10 Kymab Ltd Antibodies for use in treating conditions related to specific PCKS9 variants and associated diagnostic methods
DK3209685T3 (da) * 2014-10-23 2019-07-29 Singh Molecular Medicine Llc Enkeltdomæneantistoffer rettet mod intracellulære antigener
EP3271405A1 (fr) 2015-03-20 2018-01-24 Aarhus Universitet Inhibiteurs de pcsk9 pour le traitement de troubles du métabolisme des lipoprotéines
WO2016156474A1 (fr) * 2015-03-31 2016-10-06 Vhsquared Limited Polypeptide comprenant un domaine variable de chaîne d'immunoglobuline qui se lie à la toxine a de clostridium difficile
EP3277713A1 (fr) * 2015-03-31 2018-02-07 VHsquared Limited Polypeptides
AU2016239948B2 (en) 2015-03-31 2022-03-17 Sorriso Pharmaceuticals, Inc. Polypeptides
EP3798232A1 (fr) 2015-07-16 2021-03-31 Inhibrx, Inc. Protéines de fusion se liant à dr5 multivalentes et multispécifiques
MX2018007925A (es) 2015-12-31 2018-08-29 Jiangsu Hengrui Medicine Co Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo.
EP3401336A4 (fr) * 2016-01-05 2020-01-22 Jiangsu Hengrui Medicine Co., Ltd. Anticorps anti-pcsk9, fragment de liaison à l'antigène associé et application médicale associée
AU2017329799A1 (en) 2016-09-20 2019-04-11 Aarhus Universitet Compounds for treatment of lipoprotein metabolism disorders
MX2019012083A (es) 2017-04-13 2019-11-21 Cadila Healthcare Ltd Nueva vacuna de peptidos contra la pcsk9.
CN109897110B (zh) * 2017-12-08 2022-05-17 深圳华大生命科学研究院 纳米抗体及其制备方法
CN110872353B (zh) * 2018-09-03 2021-05-04 深圳华大基因科技有限公司 特异性结合pcsk9抗原的纳米抗体及其制备方法和应用
EP3911648A4 (fr) 2019-01-18 2022-10-26 Astrazeneca AB Inhibiteurs de pcsk9 et leurs procédés d'utilisation
CA3144567A1 (fr) 2019-06-21 2020-12-24 Scott Crowe Polypeptides
US20220242945A1 (en) 2019-06-21 2022-08-04 Sorriso Pharmaceuticals, Inc. Polypeptides
WO2021159235A1 (fr) * 2020-02-10 2021-08-19 深圳华大生命科学研究院 Anticorps à domaine unique pour pcsk9 et son application

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69326967T2 (de) 1992-01-17 2000-06-15 Lakowicz Joseph R Phasenmodulationsenergieübertragungsfluoroimmunassay
AU2002349228B2 (en) 2001-11-30 2007-06-14 National Research Council Of Canada Self-assembly molecules
WO2008057457A2 (fr) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
WO2008063382A2 (fr) * 2006-11-07 2008-05-29 Merck & Co., Inc. Antagonistes de pcsk9
TW200906439A (en) * 2007-04-13 2009-02-16 Novartis Ag Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (PCSK9)
JP2011501952A (ja) 2007-10-26 2011-01-20 シェーリング コーポレイション 脂質障害およびコレステロール障害を治療するための抗ｐｃｓｋ９および方法
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
CA2771464C (fr) 2009-08-18 2019-10-29 National Research Council Of Canada Criblage de proteines candidates
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)

Also Published As

Publication number Publication date
CA2859226A1 (fr) 2013-06-27
CN104169304A (zh) 2014-11-26
EP2794661B1 (fr) 2019-03-06
US9879093B2 (en) 2018-01-30
JP2015503905A (ja) 2015-02-05
EP2794661A4 (fr) 2015-09-09
EP2794661A1 (fr) 2014-10-29
JP6170940B2 (ja) 2017-07-26
CA2859226C (fr) 2020-07-21
WO2013091103A1 (fr) 2013-06-27
US20150017183A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
HK1204477A1 (en) Single domain antibodies as inhibitors of pcsk9 pcsk9
HK1201519A1 (en) Inhibitors of phosphodiesterase type 10a 10a
SMT201600238B (it) Inibitori di protein chinasi
AP3907A (en) 3-Pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
ZA201309561B (en) Novel inhibitor compounds of phosphodiestarase type 10a
EP2678018A4 (fr) Combinaison d'inhibiteurs des kinases et utilisations associées
SMT201600001B (it) Imidazopiridazine come inibitori di akt chinasi
HK1202529A1 (zh) 非典型性蛋白激酶 的噻吩並嘧啶類抑制劑
SI2670401T1 (sl) Postopki uporabe inhibitorjev ALK
AP3529A (en) Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
HK1199252A1 (en) Inhibitors of nedd8-activating enzyme nedd8-
ZA201206456B (en) Uses of dgati inhibitors
IL227924B (en) Preparations and methods of use for determining a4he
ME02167B (me) Piridinil- i pirazinil-metiloksi-aril derivati korisni kao inhibitori tirozin kinaze slezine (syk)
EP2688901A4 (fr) Inhibiteurs de 17ss-hsd1, 17ss-hsd3 et 17ss-hsd10
EP2709999A4 (fr) Composés de quinazoline-7-éther et méthodes d'utilisation
HK1199040A1 (en) Use of antibody
EP2591368A4 (fr) Procédé de détermination de la consommation d'éthanol
EP2663322A4 (fr) Nouvelles utilisations d'inhibiteurs de la cyclophiline
ZA201308697B (en) Hydroxymethylaryl-substituted pyprolotriazines as alk1 inhibitors
UA22157S (uk) Набір посуду для напоїв
AU2011903435A0 (en) Determining of locations